SCHEMBL13385607

SCHEMBL13385607

COCCOCCOCC(C)N

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CA2 P00918 1/20 0.36
HSD17B10 Q99714 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16106614 1.00 CA2 (0.36) CA2HSD17B10ALDH1A1
SCHEMBL19771000 1.00 CA2 (0.36) CA2HSD17B10ALDH1A1
SCHEMBL20181308 0.97
SCHEMBL800846 0.97
SCHEMBL20181307 0.97
SCHEMBL31360426 0.93 CA2 (0.33) CA2
SCHEMBL18905555 0.93 CA2 (0.33) CA2
SCHEMBL12269417 0.89 ALDH1A1 (0.37) HSD17B10ALDH1A1
SCHEMBL12695269 0.89 ALDH1A1 (0.37) HSD17B10ALDH1A1
Water SCHEMBL28694307 0.87 ALDH1A1 (0.35) HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2981535-B1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS TOPIVERT PHARMA LTD (GB) 2020-12-16 EP disclosed
US-10435361-B2 Kinase inhibitors TOPIVERT PHARMA LIMITED (GB) 2019-10-08 US disclosed
US-20180044288-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2018-02-15 US disclosed
US-9790174-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-17 US disclosed
US-20160376232-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-12-29 US disclosed
US-9481648-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2016-11-01 US disclosed
EP-2981535-A1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS Respivert Limited (GB) 2016-02-10 EP disclosed
WO-2014162126-A1 UREA DERIVATIVES USEFUL AS KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-10-09 WO disclosed
US-20140296208-A1 KINASE INHIBITORS TOPIVERT PHARMA LIMITED (GB) 2014-10-02 US disclosed
US-8071814-B2 Process for preparing polyetheramines CLARIANT FINANCE (BVI) LIMITED (VG) 2011-12-06 US disclosed
US-7696385-B2 Polyetheramine production method CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2010-04-13 US disclosed
US-20100069671-A1 Process For Preparing Polyetheramines CLARIANT FINANCE (BVI) LIMITED (VG) 2010-03-18 US disclosed
US-20090177013-A1 Polyetheramine Production Method CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044288-A1 KINASE INHIBITORS SYK, LYN, BTK CA2 2538/4885HSD17B10 4720/4885ALDH1A1 4408/4885
US-20090177013-A1 Polyetheramine Production Method PNMT, HRH3, HRH4 CA2 690/4885HSD17B10 1117/4885ALDH1A1 2133/4885
US-20160376232-A1 KINASE INHIBITORS LYN, SYK, LCK CA2 2848/4885HSD17B10 3142/4885ALDH1A1 3120/4885
US-10435361-B2 Kinase inhibitors SYK, LYN, BTK CA2 2538/4885HSD17B10 4720/4885ALDH1A1 4408/4885
US-20100069671-A1 Process For Preparing Polyetheramines OXER1, OXGR1, NR1H3 CA2 731/4885HSD17B10 123/4885ALDH1A1 2544/4885
US-20140296208-A1 KINASE INHIBITORS SYK, LYN, BTK CA2 2538/4885HSD17B10 4720/4885ALDH1A1 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.